BVS

8.51

4.06% -0.36

Pre-mercato: 8.55 0.04 +0.47%

Bioventus Inc (BVS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$8.87

Aprire:

$8.86

Volume 24 ore:

711.12K

Relative Volume:

1.41

Capitalizzazione di mercato:

$576.54M

Reddito:

$568.09M

Utile/perdita netta:

$27.27M

Rapporto P/E:

25.98

EPS:

0.3276

Flusso di cassa netto:

$71.41M

1 W Prestazione:

-8.30%

1M Prestazione:

-12.00%

6M Prestazione:

+12.12%

1 anno Prestazione:

+29.73%

Intervallo 1D:

$8.51

$8.90

Intervallo di 1 settimana:

$8.39

$9.575

Portata 52W:

$5.81

$11.25

Bioventus Inc Stock (BVS) Company Profile

Nome

Bioventus Inc

Settore

Healthcare (1106)

Industria

Medical Devices (143)

Telefono

(919) 474-6700

Indirizzo

4721 EMPEROR BOULEVARD, SUITE 100, DURHAM

Dipendente

940

Cinguettio

Prossima data di guadagno

2026-05-06

Ultimi documenti SEC

BVS's Discussions on Twitter

Compare BVS vs ABT, SYK, MDT, BSX, EW

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BVS Bioventus Inc	8.51	600.93M	568.09M	27.27M	71.41M	0.3276
ABT Abbott Laboratories	85.60	150.32B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	305.09	117.93B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	73.81	97.02B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	48.31	72.99B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.47	49.50B	6.30B	1.07B	1.09B	1.8406

Bioventus Inc Stock (BVS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-27	Iniziato	CJS Securities	Market Outperform
2026-02-09	Iniziato	Barrington Research	Outperform
2025-07-07	Iniziato	Cantor Fitzgerald	Overweight
2024-12-17	Aggiornamento	JP Morgan	Underweight → Neutral
2023-12-07	Aggiornamento	Canaccord Genuity	Hold → Buy
2023-08-09	Aggiornamento	Craig Hallum	Hold → Buy
2022-11-22	Downgrade	Craig Hallum	Buy → Hold
2022-11-09	Downgrade	Canaccord Genuity	Buy → Hold
2022-11-09	Downgrade	JP Morgan	Overweight → Underweight
2022-03-15	Iniziato	Craig Hallum	Buy
2021-11-15	Ripresa	Morgan Stanley	Overweight
2021-11-10	Ripresa	JP Morgan	Overweight
2021-07-01	Downgrade	Goldman	Buy → Neutral
2021-03-08	Iniziato	Canaccord Genuity	Buy
2021-03-08	Iniziato	Goldman	Buy
2021-03-08	Iniziato	JP Morgan	Overweight
2021-03-08	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Bioventus Inc Borsa (BVS) Ultime notizie

06:46 AM

Transcript: Bioventus Q1 2026 Earnings Conference Call - Benzinga

06:46 AM

May 30, 2026

Bioventus (BVS) Q1 2026 Earnings Transcript - AOL.com

May 30, 2026

May 29, 2026

Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - sharewise.com

May 29, 2026

May 27, 2026

Bioventus (BVS) Q1 2026 Earnings: Strong EPS Beat Amidst Market SkepticismDiluted EPS Report - thelegaladvocate.com

May 23, 2026

May 22, 2026

BVS Maintained by Barrington Research -- Price Target at $14.00 - GuruFocus

May 22, 2026

Bioventus Inc.Class A Common Stock (NQ: BVS - The Chronicle-Journal

May 22, 2026

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It - Benzinga

May 22, 2026

Bioventus Is Maintained at Outperform by Barrington Research - Moomoo

May 22, 2026

Bioventus Inc. Files Form 8-K: Corporate Details, Stock Information, and SEC Compliance for May 2026 - Minichart

May 22, 2026

May 21, 2026

FDA reclassifies Bioventus bone growth stimulator; company maintains 2026 outlook - Investing.com UK

May 21, 2026

FDA reclassifies Bioventus bone growth stimulator; company maintains 2026 outlook By Investing.com - Investing.com South Africa

May 21, 2026

Bioventus Inc stated in a filing with the SEC that expected adjustments to reimbursement policies related to the Exogen bone healing system are not anticipated to have a material impact on the company’s financial position for fiscal year 2026. - Bitget

May 21, 2026

According to documents submitted to the U.S. Securities and Exchange Commission, SEACOR Marine Holdings Inc. expects its newly built platform supply vessels to be delivered successively in the fourth quarter of 2026 and the first quarter of 2027. - Bitget

May 21, 2026

GE Vernova Inc. announces the acquisition of Robotech Automation to accelerate advancements in its robotics and automation capabilities. - Bitget

May 21, 2026

According to documents submitted to the U.S. Securities and Exchange Commission, the U.S. Food and Drug Administration completed the reclassification of Bioventus Inc.'s Exogen ultrasound bone healing system on April 16, 2026. - Bitget

May 21, 2026

FDA reclassifies bone growth stimulators; Bioventus says 2026 guidance unchanged - TradingView

May 21, 2026

CMS reimbursement shifts leave Bioventus (NASDAQ: BVS) 2026 guidance intact - Stock Titan

May 21, 2026

Is Bioventus (BVS) Stock Undervalued Right Now? - Yahoo Finance

May 21, 2026

May 18, 2026

Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance

May 18, 2026

May 17, 2026

(BVS) Volatility Zones as Tactical Triggers - Stock Traders Daily

May 17, 2026

May 15, 2026

Bioventus (BVS) Q1 2026 Earnings: EPS $0.15 Beats EstimatesHot Community Stocks - Newser

May 15, 2026

Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are - Sahm

May 15, 2026

May 14, 2026

Bioventus' (NASDAQ:BVS) Solid Earnings Are Supported By Other Strong Factors - Yahoo Finance

May 14, 2026

May 12, 2026

TradingKey - TradingKey

May 12, 2026

May 08, 2026

Wall Street analysts see a 38.97% upside in Bioventus (BVS): Can the stock really move this high? - MSN

May 08, 2026

Wall Street Analysts See a 38.97% Upside in Bioventus (BVS): Can the Stock Really Move This High? - Yahoo Finance

May 08, 2026